ReviewTargeted oncology2026
Claudin-18.2 in Gastric and Gastroesophageal Junction Adenocarcinoma: From Biology to Therapeutic Targeting: A Narrative Review.
Review in Targeted oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric and gastroesophageal junction adenocarcinoma remains associated with a poor prognosis despite recent therapeutic advances. Claudin-18.2, a tight junction protein normally restricted to gastric epithelial cells, has emerged as a clinically validated and therapeutically actionable biomarker due to its preserved expression and aberrant membrane accessibility in malignant tissues. We conducted a narrative review of the literature (PubMed/MEDLINE and ClinicalTrials.gov; January 2000-December 2025) to summarize current knowledge on Claudin-18.2 biology, expression patterns, clinical relevance, and therapeutic targeting in gastric and gastroesophageal junction adenocarcinoma. Claudin-18.2 is frequently retained in gastric and gastroesophageal junction adenocarcinoma and can be reliably assessed using standardized immunohistochemistry. The phase III SPOTLIGHT and GLOW trials demonstrated that zolbetuximab significantly improves progression-free survival and overall survival when combined with first-line chemotherapy in Claudin-18.2-positive (moderate [2+] to strong [3+] membranous staining in ≥ 75% of tumor cells), human epidermal growth factor receptor 2-negative advanced disease. Emerging strategies, including antibody-drug conjugates, bispecific antibodies, and chimeric antigen-T-cell therapies, are under active investigation. Claudin-18.2 has established itself as a validated therapeutic target in gastric and gastroesophageal junction adenocarcinoma. Its integration into clinical practice reflects a shift toward biomarker-driven, multi-target treatment algorithms, although challenges remain regarding assay standardization, resistance mechanisms and optimal therapeutic sequencing alongside human epidermal growth factor receptor 2, microsatellite instability/deficient mismatch repair, and programmed death-ligand 1.
Indexed as
Identifiers
42599559What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.